These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19712605)

  • 1. [Controversy on biosimilar drugs and their therapeutic exchange].
    Dorantes Calderón B
    Farm Hosp; 2009; 33(4):181-2. PubMed ID: 19712605
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biosimilar drugs – just as good, and much cheaper].
    Goll GL
    Tidsskr Nor Laegeforen; 2019 Mar; 139(6):. PubMed ID: 30917643
    [No Abstract]   [Full Text] [Related]  

  • 3. The rise of the biosimilar.
    McCamish M; Woollett G
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):597-9. PubMed ID: 23234317
    [No Abstract]   [Full Text] [Related]  

  • 4. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 5. Using Clinical PK/PD Studies to Support No Clinically Meaningful Differences Between a Proposed Biosimilar and the Reference Product.
    Zhu P; Ji P; Wang Y
    AAPS J; 2018 Aug; 20(5):89. PubMed ID: 30094524
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars in rheumatology: the wind of change.
    Schneider CK
    Ann Rheum Dis; 2013 Mar; 72(3):315-8. PubMed ID: 23390018
    [No Abstract]   [Full Text] [Related]  

  • 8. Mini Focus: bioanalysis of biosimilars.
    Amaravadi L; Marini J
    Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
    [No Abstract]   [Full Text] [Related]  

  • 9. European perspective on biosimilars.
    Wadhwa M; Thorpe R
    Bioanalysis; 2013 Mar; 5(5):521-4. PubMed ID: 23425266
    [No Abstract]   [Full Text] [Related]  

  • 10. [Equivalence, equity and evidence for the use of biosimilar drugs.].
    Trotta F; Addis A
    Recenti Prog Med; 2017 Jan; 108(1):11-13. PubMed ID: 28151523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars.
    Malozowski S
    Arq Bras Endocrinol Metabol; 2011 Nov; 55(8):669. PubMed ID: 22218453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competition in the Age of Biosimilars.
    Chandra A; Vanderpuye-Orgle J
    JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-inferiority versus equivalence clinical trials in assessing biological products.
    Pinto VF
    Sao Paulo Med J; 2011 May; 129(3):183-4. PubMed ID: 21755255
    [No Abstract]   [Full Text] [Related]  

  • 14. Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don't know.
    Li E; Hoffman JM
    J Natl Compr Canc Netw; 2013 Apr; 11(4):368-72. PubMed ID: 23584340
    [No Abstract]   [Full Text] [Related]  

  • 15. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of biosimilar drugs in psoriasis: a position paper.
    Carretero Hernández G; Puig L;
    Actas Dermosifiliogr; 2015 May; 106(4):249-51. PubMed ID: 25712906
    [No Abstract]   [Full Text] [Related]  

  • 17. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: State of Clinical and Regulatory Science.
    Klein AV; Wang J; Feagan BG; Omoto M
    J Pharm Pharm Sci; 2017; 20(1):332-348. PubMed ID: 29145936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
    Sivendran R; Ramírez J; Ramchandani M; Liu J
    Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.